检索历史 清除

近年来中国恶性肿瘤发病率逐年升高，但肿瘤领域创新药物的出现使得肿瘤患者的生存期得到了延长，恶性肿瘤逐渐成为一种慢病。50%的活动性恶性肿瘤患者伴有不同程度的肾脏损伤，肾脏损伤可以由肿瘤本身所致，更多的是肿瘤治疗过程中导致的急性或慢性肾脏损伤，临床表现包括急性肾损伤、慢性肾脏病、蛋白尿、电解质紊乱等。目前肿瘤合并慢性肾脏病患者的药物剂量调整等缺乏专业的指导和管理，中华医学会临床药学分会联合全国多学科专家制定肿瘤合并慢性肾脏病患者抗肿瘤治疗药物用药指导中国专家共识（2024版），共识基于临床循证证据，采用德尔菲法和专家访谈及研讨，涵盖肿瘤合并慢性肾脏病患者的评估方法、慢性肾脏病患者的抗肿瘤药物用药指导方案。同时按照化学治疗药物、小分子靶向药物、抗体类药物等分类，对抗肿瘤药物的选择及剂量调整推荐意见，为临床ManBetX万博官网地址下载 提供切实可行的科学指导。

The incidence of malignant tumors has steadily increased year by year in China in recent decades. The emergence of innovative anti-cancer drugs has bolstered the prognosis of cancer patients, making it a chronic disease. Kidney injuries are frequent complications of cancer treatment clinically manifested as acute kidney injury (AKI), chronic kidney disease (CKD), proteinuria, and electrolyte disorders, etc. Although kidney injuries affect up to 50% of the patients, there is a lack of professional management guidance for anti-cancer drug dosage adjustment. The clinical pharmacology branch of the Chinese Medical Association has initiated the "Chinese expert consensus on the guidance of anti-tumor drugs for patients with tumor combined chronic kidney disease (2024 edition)". We unified national multidisciplinary experts to analyze clinical evidence with the Delphi method, and conducted expert interviews and seminars focusing on kidney function assessment, anti-tumor drug dosage adjustment for kidney disease patients. We make recommendations on selection and dose adjustment of anti-tumor drugs (chemotherapy, small molecules and antibodies) according to chemotherapeutic drug classifications, providing practical and feasible scientific guidance for clinicians.